Literature DB >> 23069849

Polymorphism in protein tyrosine phosphatase receptor delta is associated with the risk of clear cell renal cell carcinoma.

Yan Du1, Tong Su, Xiaojie Tan, Xiaopan Li, Jiaxin Xie, Guoping Wang, Jian Shen, Jianguo Hou, Guangwen Cao.   

Abstract

Clear cell renal cell carcinoma (ccRCC) is a common urological malignancy. Our previous study has indicated that the protein tyrosine phosphatase receptor type delta (PTPRD) gene may play a role. To determine the effect of PTPRD genetic polymorphisms on ccRCC occurrence and progression, a total of 377 ccRCC cases and 754 matched controls were enrolled in the study. DNA sequencing and genotyping, and immunohistochemistry were conducted to test the associations of genotypes with ccRCC risk and PTPRD expression level in somatic tissues. The C allele of PTPRD rs2279776 was associated with a higher risk of ccRCC (per allele OR=1.23, P=0.03). Patients without distant metastasis at the time of surgery were followed for a median of 33.1months. Overall survival was not different between different rs2279776 genotype groups (P=0.30). The C allele was associated with a higher percentage of negative immunostaining in adjacent normal renal tissues (P=0.02). PTPRD rs2279776 SNP may be a novel genetic risk factor of ccRCC.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23069849     DOI: 10.1016/j.gene.2012.09.094

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  8 in total

1.  Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis.

Authors:  Berenice Ortiz; Armida W M Fabius; Wei H Wu; Alicia Pedraza; Cameron W Brennan; Nikolaus Schultz; Kenneth L Pitter; Jacqueline F Bromberg; Jason T Huse; Eric C Holland; Timothy A Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

Review 2.  PTPRD: neurobiology, genetics, and initial pharmacology of a pleiotropic contributor to brain phenotypes.

Authors:  George R Uhl; Maria J Martinez
Journal:  Ann N Y Acad Sci       Date:  2019-01-15       Impact factor: 5.691

3.  Host genetic variants and gene expression patterns associated with Epstein-Barr virus copy number in lymphoblastoid cell lines.

Authors:  Charlotte J Houldcroft; Velislava Petrova; Jimmy Z Liu; Dan Frampton; Carl A Anderson; Astrid Gall; Paul Kellam
Journal:  PLoS One       Date:  2014-10-07       Impact factor: 3.240

4.  Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis.

Authors:  Berenice Ortiz; Julie R White; Wei H Wu; Timothy A Chan
Journal:  Oncotarget       Date:  2014-08-30

5.  Protein tyrosine phosphatase receptor-type δ acts as a negative regulator suppressing breast cancer.

Authors:  Xiaotang Yu; Fan Zhang; Jun Mao; Ying Lu; Jiazhi Li; Wei Ma; Shujun Fan; Chunying Zhang; Qing Li; Bo Wang; Bo Song; Lianhong Li
Journal:  Oncotarget       Date:  2017-10-24

6.  CD146 Promoter Polymorphism (rs3923594) Is Associated with Recurrence of Clear Cell Renal Cell Carcinoma in Chinese Population.

Authors:  Gang Feng; Hou-Bao Huang; Xiao-Bing Ye; Peng Zhang; Jian-Jun Huang; Li-Zhu Huang; Long Cheng; Chun Pu; Guorong Li
Journal:  Dis Markers       Date:  2017-05-24       Impact factor: 3.434

7.  A genetic polymorphism affects the risk and prognosis of renal cell carcinoma: association with follistatin-like protein 1 expression.

Authors:  Yan Liu; Xue Han; Yongwei Yu; Yibo Ding; Chong Ni; Wenbin Liu; Xiaomei Hou; Zixiong Li; Jianguo Hou; Dan Shen; Jianhua Yin; Hongwei Zhang; Timothy C Thompson; Xiaojie Tan; Guangwen Cao
Journal:  Sci Rep       Date:  2016-05-26       Impact factor: 4.379

8.  Genetic scores based on risk-associated single nucleotide polymorphisms (SNPs) can reveal inherited risk of renal cell carcinoma.

Authors:  Yishuo Wu; Ning Zhang; Kaiwen Li; Haitao Chen; Xiaolin Lin; Yang Yu; Yuancheng Gou; Jiangang Hou; Deke Jiang; Rong Na; Xiang Wang; Qiang Ding; Jianfeng Xu
Journal:  Oncotarget       Date:  2016-04-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.